The quarter’s largest deals reflect this binary focus, according to the MoneyTree Report from PricewaterhouseCoopers, the National Venture Capital Association and Thomson Reuters, publisher of this blog. Six have to do with the Internet or IT. Three are connected to health care. One is a cleantech transaction.
The second quarter saw a slight uptick in early stage financings. Seed and early stage fundings across all industries accounted for 48% of total deals in the quarter, up from 46% in the first quarter, the MoneyTree Report shows.
But large deals were still in vogue. Eight transactions came in at $100 million or more, including one at $165 million. Average deal size for the quarter was up 8% from a year ago to $8 million. Among later stage transactions, it rose to $11.5 million, up 40% from a year ago and topping the $10.8 million of the first quarter of 2010. It was the largest average deal size for later stage companies since the first quarter of 2004.
Why the venture community would be willing to put big pots of money in late stage startups is no mystery. Exit markets are heating up, especially for hot Internet IPO-bound social media companies. If a GP hasn’t yet climbed aboard the train, better run for the caboose.
What follows is a slideshow of the quarter’s top deals with transaction amount and backers. Earlier today were reported on the MoneyTree numbers.
Location: Cambridge, MA
Business Description: Supplies Therapies For Autoimmune Disease And Cancer
Stage Of Development: Later Stage
Deal Size: $77 million
Venture Backers: Credit Suisse Private Equity, Undisclosed Firms